Management of Crohn’s disease from efficacy, quality of life and health economic perspectives

The expectations of the physician and patient in the modern management of Crohn’s disease have moved on from alleviation of symptoms whenever relapses occur, to sustained maintenance of remission and mucosal healing. The majority of treatment costs are as a consequence of hospitalizations and surgery. These heightened therapeutic goals are leading to expectations that management costs will decrease. Health-related quality of life can be measured by validated disease-specific tools in Crohn’s disease, and such measurements are now forming common outcome measures in clinical trials of new therapies in Crohn’s disease. This review gives an overview of patient-focused management of Crohn’s disease and the rapid evolution in therapy, with pharmacoeconomic analysis where available.

[1]  F. Casellas,et al.  Factors affecting health related quality of life of patients with inflammatory bowel disease , 2001, Quality of Life Research.

[2]  M. Peppercorn,et al.  Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. , 2003, Gastroenterology.

[3]  R. Kozarek,et al.  Immunomodulators and “On Demand” Therapy with Infliximab in Crohn's Disease: Clinical Experience with 400 Infusions , 2003, American Journal of Gastroenterology.

[4]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[5]  Subrata Ghosh,et al.  Natalizumab for active Crohn's disease. , 2003, The New England journal of medicine.

[6]  J. Raftery,et al.  Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease. , 2003, Health technology assessment.

[7]  C. Mitton.  Funding the new biologics--a health economic critique of the CCOHTA report: infliximab for the treatment of Crohn's disease. , 2002, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[8]  H. König,et al.  Validation of the EuroQol questionnaire in patients with inflammatory bowel disease , 2002, European journal of gastroenterology & hepatology.

[9]  J. Rubenstein,et al.  Infliximab Decreases Resource Use Among Patients With Crohn's Disease , 2002, Journal of clinical gastroenterology.

[10]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[11]  S. Ghosh,et al.  Is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? , 2002 .

[12]  T. Ahmad,et al.  The molecular classification of the clinical manifestations of Crohn's disease. , 2002, Gastroenterology.

[13]  D. Hommes,et al.  Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. , 2002, Gastroenterology.

[14]  S. Ghosh,et al.  Clinical use of Infliximab in Crohn’s disease: the Edinburgh experience , 2001, Alimentary pharmacology & therapeutics.

[15]  R. Pounder,et al.  A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active crohn's disease , 2001 .

[16]  A. Zinsmeister,et al.  The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. , 2001, Gastroenterology.

[17]  J. Udall,et al.  Use of Infliximab in Pediatric Patients with Inflammatory Bowel Disease , 2001, The Annals of pharmacotherapy.

[18]  A. Forbes,et al.  Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease , 2001, Gut.

[19]  S. Targan,et al.  An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. , 2001, Gastroenterology.

[20]  E. Hahn,et al.  Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. , 2001, Gastroenterology.

[21]  A. Ekbom,et al.  A 10‐year survey of inflammatory bowel diseases—drug therapy, costs and adverse reactions , 2001, Alimentary pharmacology & therapeutics.

[22]  A. Pisani,et al.  Oral tacrolimus long‐term therapy in patients with Crohn’s disease and steroid resistance , 2001, Alimentary pharmacology & therapeutics.

[23]  W. Reinisch,et al.  Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease? , 2001, American Journal of Gastroenterology.

[24]  W. Sandborn,et al.  Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients , 2000, American Journal of Gastroenterology.

[25]  R. Enns,et al.  Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics. , 2001, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

[26]  P. Rutgeerts,et al.  Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease , 2000 .

[27]  P. Rutgeerts,et al.  Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. , 2000, Gastroenterology.

[28]  S. Kugathasan,et al.  Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease , 2000, American Journal of Gastroenterology.

[29]  S. Nikolaus,et al.  Mechanisms in failure of infliximab for Crohn's disease , 2000, The Lancet.

[30]  J. Walker-Smith,et al.  Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease , 2000, Gut.

[31]  G. Greenberg,et al.  Quality of life rapidly improves with budesonide therapy for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. , 2000 .

[32]  M. Bala,et al.  Annual cost of care for Crohn's disease: a payor perspective , 2000, American Journal of Gastroenterology.

[33]  I. Bjarnason,et al.  Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. , 2000, Gastroenterology.

[34]  C. Bernstein,et al.  Direct hospital costs for patients with inflammatory bowel disease in a Canadian Tertiary Care University Hospital , 2000, American Journal of Gastroenterology.

[35]  R. Cohen,et al.  The cost of hospitalization in Crohn's disease , 2000, American Journal of Gastroenterology.

[36]  D. Macintosh,et al.  Anti-tuberculous therapy for maintaining remission of Crohn's disease. , 2000, The Cochrane database of systematic reviews.

[37]  S. Hanauer,et al.  Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. , 1999, Gastroenterology.

[38]  S. Targan,et al.  An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. , 1999, Gastroenterology.

[39]  E. Vasiliauskas,et al.  Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. , 1999, Gastroenterology.

[40]  B. Feagan.  Review article: economic issues in Crohn’s disease — assessing the effects of new treatments on health‐related quality of life , 1999, Alimentary pharmacology & therapeutics.

[41]  W. Sandborn,et al.  Successful management of Crohn's disease of the ileoanal pouch with infliximab. , 1999, Gastroenterology.

[42]  A. Buchman,et al.  Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. , 1999, Gastroenterology.

[43]  P. Rutgeerts,et al.  Infliximab for the treatment of fistulas in patients with Crohn's disease. , 1999, The New England journal of medicine.

[44]  J. Sciubba,et al.  Thalidomide for the treatment of oral aphthous ulcers in Crohn's disease. , 1999, Journal of pediatric gastroenterology and nutrition.

[45]  M. Neurath,et al.  Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn’s disease , 1998, Gut.

[46]  A. Weaver,et al.  Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. , 1999, Inflammatory bowel diseases.

[47]  R. Newcombe,et al.  Controlled trial of antituberculous chemotherapy in Crohn's disease: a five year follow up study. , 1998, Gut.

[48]  Subrata Ghosh,et al.  5 Crohn's disease: nutrition and nutritional therapy , 1998 .

[49]  A. Ferguson,et al.  Crohn's disease: nutrition and nutritional therapy. , 1998, Bailliere's clinical gastroenterology.

[50]  A. Ekbom,et al.  Inflammatory bowel diseases: health care and costs in Sweden in 1994. , 1997, Scandinavian journal of gastroenterology.

[51]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[52]  M. Vatn,et al.  Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990-93. , 1997, Scandinavian journal of gastroenterology.

[53]  W. Sandborn.  Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. , 1997, The American journal of gastroenterology.

[54]  J. Sanderson,et al.  Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. , 1997, The Journal of antimicrobial chemotherapy.

[55]  M. Kamm,et al.  Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease , 1997, The Lancet.

[56]  R. Modigliani,et al.  Treatment of severe Crohn's disease with anti‐CD4 monoclonal antibody , 1996, Alimentary pharmacology & therapeutics.

[57]  W. Fleig,et al.  Omega-3 Fatty Acids and Low Carbohydrate Diet for Maintenance of Remission in Crohn's Disease: A Randomized Controlled Multicenter Trial , 1996 .

[58]  M. Campieri,et al.  Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. , 1996, The New England journal of medicine.

[59]  E. Cabré,et al.  How effective is enteral nutrition in inducing clinical remission in active Crohn's disease? A meta-analysis of the randomized clinical trials. , 1995, JPEN. Journal of parenteral and enteral nutrition.

[60]  D. Hommes,et al.  Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). , 1995, Gastroenterology.

[61]  A. Griffiths,et al.  Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. , 1995, Gastroenterology.

[62]  P. Munkholm,et al.  Frequency of glucocorticoid resistance and dependency in Crohn's disease. , 1994, Gut.

[63]  J. Hay,et al.  Inflammatory Bowel Disease: Costs‐of-Illness , 1992, Journal of clinical gastroenterology.

[64]  J. Hay,et al.  Inflammatory Bowel Disease: Medical Cost Algorithms , 1992, Journal of clinical gastroenterology.